|Free Dividend Report|
|Stock Splits Calendar|
|ANX Stock Split History|
|Preferred Stock Newsletter|
|Top Option Ideas|
|Stock Message Boards|
ANX (ANX) has 1 split in our ANX split history database. The split for ANX took place on April 26, 2010. This was a 1 for 25 reverse split, meaning for each 25 shares of ANX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split.
When a company such as ANX conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ANX split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ANX shares, starting with a $10,000 purchase of ANX, presented on a split-history-adjusted basis factoring in the complete ANX split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-53.61%|
|ADVENTRX Pharmaceuticals is a development stage biopharmaceutical company focused on developing proprietary product candidates. Co.'s lead product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that is designed to improve microvascular blood flow with potential applications in treating a range of diseases and conditions, such as complications arising from sickle cell disease. In addition, Co. is developing ANX-514, a detergent-free formulation of the chemotherapy drug docetaxel, an intravenously-injected chemotherapy drug used to treat solid tumors. According to our ANX split history records, ANX has had 1 split.|
|ANX Split History Table|
|04/26/2010||1 for 25|
|Materials Stock Splits|
|ANX is categorized under the Materials sector; below are some other companies in the same sector that also have a history of stock splits:|